- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT04590326
Tutkimus REGN5668:sta annettuna yhdessä kemiplimabin tai REGN4018:n kanssa aikuisilla naisilla, joilla on uusiutuva munasarjasyöpä
Vaiheen 1/2 tutkimus REGN5668:sta (MUC16xCD28, kostimulatorinen bispesifinen) annettuna yhdessä kemiplimabin tai REGN4018:n (MUC16xCD3) kanssa
This study is researching an investigational drug called REGN5668 :
- alone or,
- combined with cemiplimab (also known as REGN2810) or,
- combined with both cemiplimab and fianlimab (also known as REGN3767), or
- combined with ubamatamab (also known as REGN4018), with or without sarilumab.
The main purposes of this study are to:
- Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus
- Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus
This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.
The study is looking at several other research questions, including:
- Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
- How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
- How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood
- To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer
Tutkimuksen yleiskatsaus
Tila
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
- Vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Clinical Trials Administrator
- Puhelinnumero: 844-734-6643
- Sähköposti: clinicaltrials@regeneron.com
Opiskelupaikat
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgia, 3000
- Rekrytointi
- Universitair Ziekenhuis Leuven
-
-
-
-
-
São Paulo, Brasilia, 01509-010
- Rekrytointi
- AC Camargo Cancer Center, Fundacao Antonio Prudente
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilia, 90619-900
- Rekrytointi
- Centro de Pesquisa em Oncologia PUCRS
-
-
São Paulo
-
Barretos, São Paulo, Brasilia, 14784-400
- Rekrytointi
- Fundacao Pio XII - Hospital de Cancer de Barretos
-
Sorocaba, São Paulo, Brasilia, 18065-100
- Rekrytointi
- Unimed Sorocaba
-
-
-
-
-
Girona, Espanja, 17007
- Rekrytointi
- Institut Catala dOncologia Girona
-
Madrid, Espanja, 28040
- Rekrytointi
- Hospital Universitario Fundacion Jimenez
-
Madrid, Espanja, 28040
- Rekrytointi
- Ciudad Universitaria
-
Madrid, Espanja, 28041
- Rekrytointi
- Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
-
-
A Coruna
-
Santiago de Compostela, A Coruna, Espanja, 15706
- Rekrytointi
- Hospital Clinico Universitario Santiago de Compostela
-
-
-
-
-
Villejuif, Ranska, 94805
- Rekrytointi
- Institut Gustave Roussy
-
-
Auvergne-Rhône
-
Pierre-Bénite, Auvergne-Rhône, Ranska, 69310
- Rekrytointi
- Hopital Lyon Sud
-
-
Bourgogne-Franche-Comté
-
Dijon, Bourgogne-Franche-Comté, Ranska, 21000
- Rekrytointi
- Centre Georges Francois Leclerc
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Ranska, 33076
- Rekrytointi
- Institut Bergonie
-
-
Normandy
-
Caen, Normandy, Ranska, 14076
- Rekrytointi
- Centre Francois Baclesse (CFB)
-
-
-
-
California
-
Duarte, California, Yhdysvallat, 91010
- Rekrytointi
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Yhdysvallat, 92618
- Rekrytointi
- The City of Hope Orange County Lennar Foundation Cancer Center
-
Orange, California, Yhdysvallat, 92868
- Rekrytointi
- Chao Family Comprehensive Cancer Center
-
-
Florida
-
Tampa, Florida, Yhdysvallat, 33612
- Valmis
- H. Lee Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60611
- Rekrytointi
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
-
Chicago, Illinois, Yhdysvallat, 60637
- Rekrytointi
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02114
- Rekrytointi
- Massachusetts General Hospital
-
Boston, Massachusetts, Yhdysvallat, 02215
- Rekrytointi
- Dana Farber Cancer Institute Brookline Avenue
-
-
Michigan
-
Detroit, Michigan, Yhdysvallat, 48201
- Rekrytointi
- Karmanos Cancer Institute
-
-
New York
-
New York, New York, Yhdysvallat, 10065
- Rekrytointi
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Yhdysvallat, 43210
- Rekrytointi
- The Ohio State University Wexner Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19104
- Rekrytointi
- Perelman School of Medicine at the University of Pennsylvania
-
-
Washington
-
Seattle, Washington, Yhdysvallat, 98109
- Rekrytointi
- Seattle Cancer Care Alliance at South Lake Union - G3630
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Key Inclusion Criteria:
- Ovarian Cancer Cohorts Only: Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy as defined in the protocol
- Expansion cohorts only: Has at least 1 lesion that is measurable by RECIST 1.1 as described in the protocol.
- Has a serum CA-125 level ≥2x ULN (in screening, not applicable to endometrial cohorts)
- Has adequate organ and bone marrow function as defined in the protocol
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Has a life expectancy of at least 3 months
- Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-PD-1 therapy and platinum-based chemotherapy as described in the protocol
Key Exclusion Criteria:
- Current or recent (as defined in the protocol) treatment with an investigational agent, systemic biologic therapy, or anti-cancer immunotherapy
- Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol
- Prior treatment with a Mucin 16 (MUC16)-targeted therapy
- Ovarian Expansion cohorts only: More than 5 prior lines of systemic therapy
- Has any condition that requires ongoing/continuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug
- Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
- Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
- Has history of clinically significant cardiovascular disease as defined in the protocol
- Has known allergy or hypersensitivity to cemiplimab and/or components of study drug(s).
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Module 1
REGN5668 in combination with cemiplimab, or cemiplimab + fianlimab |
Administer per the protocol
Muut nimet:
Administer per the protocol
Muut nimet:
Administer per the protocol |
|
Kokeellinen: Module 2
REGN5668 and ubamatamab |
Administer per the protocol
Muut nimet:
Administer per the protocol
Muut nimet:
Administer per the protocol
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Incidence of Dose Limiting Toxicities (DLT)
Aikaikkuna: 42 days
|
Dose escalation phase, Module 1 |
42 days
|
|
Incidence of DLTs
Aikaikkuna: 21 days post combination administration
|
Dose escalation phase, Module 2 |
21 days post combination administration
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Aikaikkuna: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of Serious Adverse Events (SAEs)
Aikaikkuna: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of deaths
Aikaikkuna: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])
Aikaikkuna: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamab
Aikaikkuna: Through study completion, up to 5 years
|
Primary: Dose escalation phase |
Through study completion, up to 5 years
|
|
Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Aikaikkuna: Through study completion, up to 5 years
|
Primary: Dose expansion phase |
Through study completion, up to 5 years
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
ORR based on RECIST 1.1
Aikaikkuna: Through study completion, up to 5 years
|
Dose escalation phase |
Through study completion, up to 5 years
|
|
Best Overall Response (BOR) based on RECIST 1.1
Aikaikkuna: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Duration Of Response (DOR) based on RECIST 1.1
Aikaikkuna: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Disease Control Rate (DCR) based on RECIST 1.1
Aikaikkuna: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Progression-Free Survival (PFS) based on RECIST 1.1
Aikaikkuna: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Cancer Antigen 125 (CA-125) change from baseline after treatment with REGN5668 in combinations with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Aikaikkuna: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Concentration of REGN5668 in serum over time when dosed alone and in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab
Aikaikkuna: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against REGN5668
Aikaikkuna: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against ubamatamab
Aikaikkuna: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against cemiplimab
Aikaikkuna: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against fianlimab
Aikaikkuna: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Clinical Trial Management, Regeneron Pharmaceuticals
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Urogenitaaliset sairaudet
- Sukuelinten sairaudet
- Endokriinisen järjestelmän sairaudet
- Patologiset prosessit
- Urogenitaaliset kasvaimet
- Neoplasmat sivustoittain
- Neoplasmat
- Naisten virtsa- ja sukupuolielinten sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet ja raskauden komplikaatiot
- Sairauden ominaisuudet
- Kohdun sairaudet
- Sukuelinten sairaudet, naiset
- Endokriinisten rauhasten kasvaimet
- Munasarjan sairaudet
- Adnexaaliset sairaudet
- Sukuelinten kasvaimet, naiset
- Sukurauhasten häiriöt
- Kohdun kasvaimet
- Munajohtimien sairaudet
- Patologiset tilat, merkit ja oireet
- Toistuminen
- Munasarjan kasvaimet
- Endometriumin kasvaimet
- Munajohtimien kasvaimet
- cemiplimab
- sarilumabi
Muut tutkimustunnusnumerot
- R5668-ONC-1938
- 2022-501904-83-00 (Ctis)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD-jaon aikakehys
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-jaon käyttöoikeuskriteerit
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- ICF
- ANALYTIC_CODE
- CSR
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .